Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.52M
Average 0.39M
SION Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Sionna Therapeutics, Inc.NASDAQ: SION
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables outflow grows to $0
Q1 FY2026 accounts receivables was $0, compared with $0 a year earlier. Trailing-twelve-month accounts receivables was $0.
Context
- Accounts receivables increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Accounts Receivables vs competitors
How SION compares with its peers on the latest reported figures
- SION's LTM Mar 2026 accounts receivables of $0 is the 8th largest of the 11 companies compared; the peer median is $14.98M.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $267.78M | +5106.7% | — | 100.7% | |
| LTM Sep 2026 | $43.84M | +19.1% | +34.8% | 64.6% | |
| LTM Mar 2026 | $36.37M | +98.7% | +25.1% | 8.5% | |
| LTM Mar 2026 | $35M | +401.4% | — | 161.9% | |
| LTM Mar 2026 | $20M | — | — | 100.0% | |
| LTM Mar 2026 | $9.97M | +11.8% | -7.4% | 3.2% | |
| LTM Sep 2026 | $265K | -134.8% | +95.9% | 236.6% | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Sep 2026 | $0 | — | — | — | |
| LTM Jun 2026 | $0 | — | — | — | |
| LTM Jun 2026 | $0 | — | — | — | |
| Peer median (excluding SION) | $14.98M | +58.9% | +29.9% | 100.0% | |
Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.